Clinical Study

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin

Alessandra D’Abramo, Claudia D’Agostino, Alessandra Oliva, Marco Iannetta, Gabriella D’Ettorre, Francesco Vullo, Massimo Mancone, Maria Rosa Ciardi, Claudio Maria Mastroianni, and Vincenzo Vullo

Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, Italy

Correspondence should be addressed to Alessandra D’Abramo; alessandra.dabramo@libero.it

Received 1 October 2013; Accepted 29 October 2013

Academic Editors: H. C. Mwandumba and J. Poudrier

Copyright © 2013 Alessandra D’Abramo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiovascular disease is increased in HIV-infected patients. Cytokines such as osteoprotegerin are implicated in atherosclerosis. The aim of our study was to evaluate the role of osteoprotegerin in the development and progression of atherosclerosis in HIV infected subjects on suppressive antiretroviral treatment. We enrolled 76 patients; 35 HIV infected men on suppressive Highly Active Antiretroviral Therapy with Framingham score <10%; 21 HIV negative individuals matched for age, gender, and Framingham score, and 20 subjects with Framingham score >10% as control groups. HIV positive subjects underwent echocardiography, electrocardiography, and heart multidetector computed tomography, whereas in HIV negative subjects, tomography was only performed in case of any abnormalities either in echocardiography or electrocardiography. In HIV positive patients, computed tomography showed stenosis in 51.4% of the subjects. Osteoprotegerin plasma levels were higher in HIV-infected patients than those in healthy controls but lower than in HIV negative subjects with Framingham score >10%. Higher osteoprotegerin plasma levels were found in HIV positive patients with grade I stenosis than in patients with grade II/III stenosis. In conclusion, in HIV infected subjects with Framingham score <10%, osteoprotegerin plasma concentrations are associated with atherosclerosis, in particular at the early stage of the process.

1. Introduction

Cardiovascular disease (CVD) is an emerging and significant cause of morbidity and mortality in HIV-infected patients [1]. HIV itself and antiretroviral drugs may contribute to the increased risk of CVD. In addition to traditional risk factors (age, smoking, dyslipidemia, and diabetes), chronic viral infection, immune activation, and inflammation play a central role in vascular damage and endothelial dysfunction [2]. Proinflammatory cytokines such as interleukin (IL)-6 and IL-1 are associated with development and progression of atherosclerosis [3–7]; furthermore, new soluble markers including osteoprotegerin (OPG) have been shown to be involved in this process. The OPG/RANK (receptor activator of NF-kappaB ligand)/RANKL (receptor activator of NF-kappaB ligand), member of TNF superfamily, is a key regulatory system in bone remodelling by regulating development and activation of osteoclasts [8–11]. Recent studies showed the implication of the OPG/RANKL system in vascular disease, especially in vascular calcification, atherosclerosis and plaque formation [12–15]. There are few data about the relationship between OPG and cardiovascular disease in HIV infection; thus, the role of OPG is not yet well established. The aim of our study was to evaluate the role of OPG in the development and progression of atherosclerosis in HIV infected subjects on suppressive antiretroviral treatment.

2. Materials and Methods

2.1. Ethics Statement. The study protocol designed according to the Helsinki Declaration II was approved by the local ethics committee. All the patients gave written informed consent to participate.
2.2. Patients. We recruited 76 patients from the Department of Public Health and Infectious Disease and the Department of Cardiovascular, Respiratory, Nephrologic and Geriatric Sciences of “Sapienza” University of Rome (Italy). Thirty-five were HIV-infected men on Highly Active Antiretroviral Therapy (HAART) since 48 weeks with undetectable viremia (<37 copies/mL) and low cardiovascular diseases risk defined by a Framingham score <10%. Subjects with diagnosis of metabolic syndrome (waist circumference: men >102 cm and women >88 cm, triglycerides ≥150 mg/dL, HDL cholesterol: men <40 mg/dL and women <50 mg/dL, blood pressure: ≥130/85 mm Hg or use of medication for hypertension, and fasting glucose ≥100 mg/dL or use of medication for hyperglycemia) were excluded [16]. As control groups we enrolled 21 HIV negative individuals matched for age, gender, and Framingham score and 20 HIV negative additional subjects with Framingham score >10%. For each patient we collected medical and family history, lifestyle, smoking status, antiretroviral therapies, HIV-RNA zenith, and nadir CD4+ cell count. Current lymphocytes T CD4+ and CD8+ cell count were determined by flow cytometric analysis (MACSQuant Analyser Miltenyi Biotec, Germany) and HIV-1 RNA plasma levels were detected by a quantitative reverse polymerase chain reaction (Amplicor HIV monitor; Roche Diagnostic System, Branchburg, NJ version 1.5, l.o.d. 37 copies/mL). Serum glucose; triglycerides; and total cholesterol, high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) were measured in blood samples. Body mass index (BMI) was calculated (kg/m²) and recorded for each individual. Stress test echocardiography and electrocardiography (ECG) were performed in all patients. Ineligible participants were females, aged <18 years, previous virological failure, recent AIDS-defining illness, coinfected with hepatitis virus, patients with other comorbidities (diabetes mellitus, arterial hypertension, kidney disease, and hormonal dysfunction).

2.3. IL-6 and Osteoprotegerin Detection. IL-6 was measured with an ELISA kit (bE Bioscience bender MedSystem, Inc Vienna, Austria). The detection limit of assay was 3.1 pg/mL. Osteoprotegerin were measured by ELISA kits (Biomedica Gruppe, Vienna Austria). The detection limit of assay was 0.12 pmol/L.

2.4. Multidetector Computed Tomography (MDTC) and Coronary Angiography (CA). The severity of CVD was evaluated in 35 HIV+ patients using a low-dose prospectively ECG-triggered CT coronary angiography protocol with 64-slice multidetector MDCT scanner (Somatom Definition Siemens medical Solution, Foreheime, Germany) [17, 18]. MDTC dataset were transferred and analyzed through a dedicated cardiac workstation (Vitrea 2.6, Vital images, USA). For the analysis, the American Heart Association (AHA) coronary arteries segmentation model was adopted and all segments with a diameter ≥1 mm at their origin were included [19, 20]. The degree of luminal stenosis was classified as mild (grade I: 30–49%), moderate (grade II: 50–69%), severe (grade III: 70–99%), or coronary occlusion (grade IV: 100%). A threshold of 50% luminal narrowing in any coronary segment greater than 1.5 mm in diameter was adopted to define clinically significant coronary stenosis. All patients with grade II and III stenosis at MDTC were considered for coronary angiography. This was performed using standard technique with angiograms evaluated by blinded operator to the MDTC results. The decision to perform coronary revascularization was made according to the recently appropriateness criteria [21, 22]. On the other hand, HIV negative subjects underwent MDTC only in case of any abnormalities either in echocardiography or ECG; in the presence of significant stenosis a coronary angiography was set up (Figure 1).

2.5. Statistical Analysis. Continuous data were analyzed with Student’s t test, whereas the nonparametric Mann-Whitney test was applied for values not normally distributed. Pearson correlation coefficient was used for correlations. Linear regression model was tested to evaluate the association between IL-6, OPG, and the grade of stenosis. Data were expressed as median and mean ± standard deviation (SD). A P value of <0.05 was considered statistically significant. Statistical analyses were performed using STATA (version 9) software (STATACorp. LP, College Station, TX).

3. Results

3.1. Characteristics of the Study Population. General characteristics of the study population are summarized in Table 1. All HIV infected subjects were males with low cardiovascular diseases risk (Framingham score <10%), mean age was 53 ± 8.8 years. 57.1% were not smokers, and BMI mean was
Table 1: Clinical characteristics.

|                      | HIV− (FS < 10%) | HIV+ | HIV− (FS > 10%) |
|----------------------|----------------|------|----------------|
| Age (M ± SD)         | 48 ± 9         | 53 ± 8.8 | 55 ± 8 |
| Sex                  | 21 M, 0 F      | 35 M, 0 F | 20 M, 0 F |
| Smoke status (n, %)  |                |      |                |
| no                   | 15 (71%)       | 20 (71.1%) | 6 (30%) |
| yes                  | 6 (29%)        | 15 (42.9%) | 14 (70%) |
| CD4+ (mmc) (M ± SD)  | 770 ± 221      | 570 ± 341.2 | 689 ± 197 |
| CD4+ % (M ± SD)      | 36 ± 9.3       | 17.3 ± 7.6 | 33.6 ± 8.7 |
| CD4+ (mmc) nadir (M ± SD) | —            | 287.7 ± 253.4 | — |
| CD4+ % nadir (M ± SD)| —              | 12.9 ± 8.7 | — |
| HIV-RNA zenith (cp/mL) (M ± SD) | —             | 257376.5 ± 346884.8 | — |
| HIV-RNA (cp/mL)      | <37            | <37   | <37            |
| Lipid-lowering therapy |                |      |                |
| no                   | 21 (100%)      | 35 (100%) | 12 (60%) |
| yes                  | 0              | 0     | 8 (40%)        |
| Systolic blood pressure (mmHg) | 114.8 ± 17.5 | 117.3 ± 15.5 | 125.8 ± 18.5 |
| Diastolic blood pressure (mmHg) | 81.8 ± 11.4 | 77.3 ± 12.5 | 88.3 ± 20.5 |
| Triglycerides (mg/dL) (M ± SD) | 113.6 ± 31 | 178.8 ± 90.2 | 198.5 ± 82 |
| Cholesterol Total (mg/dL) (M ± SD) | 150.3 ± 35.8 | 200.7 ± 51.7 | 266.3 ± 48.7 |
| Cholesterol HDL (mg/dL) (M ± SD) | 53.2 ± 16.7 | 41.8 ± 13.6 | 39.8 ± 12.6 |
| Cholesterol LDL (mg/dL) (M ± SD) | 102.5 ± 32.4 | 133.3 ± 47.2 | 172.7 ± 42.4 |
| Body mass index (kg/m²) (M ± SD) | 18.7 ± 2.5 | 20.7 ± 2.4 | 21.7 ± 2.3 |
| Framingham score      | 3.2 ± 2.1%     | 4.1 ± 3.2% | 13.4 ± 5.4% |

FS: Framingham score; M: mean; SD: standard deviation; HDL: high density lipoprotein; LDL: low density lipoprotein.

20.7 ± 2.4 kg/m². Average nadir and current lymphocytes T CD4+ cells count was 287.7 ± 253.45 cell/mmc and 570 ± 341.28 cell/mmc, respectively. The mean plasma concentrations of total cholesterol was 200 ± 51.79 mg/dL, HDL cholesterol was equal to 41.8 ± 13.67 mg/dl, LDL cholesterol was equal to 133.35 ± 47.25 mg/dl, and triglycerides were equal to 178.8 ± 90.22 mg/dl. None of the subjects was receiving lipid-lowering therapy.

3.2. Multidetector Computed Tomography and Coronary Angiography. MDCT examination was successfully and safely performed in all patients. We observed stenosis in 18/35 (51.4%) and no stenosis in 17/35 (48.6%). In patients with stenosis, 5/18 (27.7%) had mild stenosis (i.e., grade I) and 13/18 (72.3%) had grade II stenosis. As expected, no one had grade III stenosis. Among patients with grade II stenosis, 8/13 (61.5%) had 1 vessel and 5/13 (38.5%) 2 vessels coronary disease. All the plaques detected were eccentric and in 10/13 (76.9%) were soft. 13/13 (100%) patients with grade II stenosis at CT underwent CA and 6 (46.1%) underwent a percutaneous coronary intervention with application of 16 drug-eluting stents (Biosensors, Biomatrix DES). Twenty HIV negative subjects with CVD had grade II/III stenosis at MDTC and underwent CA; 8 (40%) underwent a percutaneous coronary intervention with application of 16 drug-eluting stents. Twenty-one HIV negative subjects with Framingham score <10% did not perform MDTC because of the absence of modifications at the echocardiography stress test and ECG.

3.3. Osteoprotegerin and Interleukin-6. Osteoprotegerin (OPG) plasma levels were significantly higher in HIV-infected patients than in healthy controls but lower than those in HIV negative subject with CVD (mean ± SD: 5.79 ± 2.82 versus 3.6 ± 1.7 versus 8.6 ± 4.3 pmol/L; median: 5.6 versus 3.6 versus 7 pmol/L) (P = 0.034) (Figure 2). We observed higher OPG plasma levels in HIV positive patients with mild coronary stenosis than in patients with grade II stenosis (mean ± SD: 6.1 ± 1.5 versus 5.3 ± 1.7 pmol/L; median: 6.2 versus 5.7 pmol/L) (P = 0.05) (Figure 3). Interestingly, even in the 20 HIV negative subjects with CVD, OPG plasma concentration was higher in subjects with grade I stenosis than in subjects with grade II stenosis (9 ± 4.1 versus 8.1 ± 4.9 pmol/L) (P = 0.2). We observed negative correlation between OPG plasma levels and total cholesterol (P = 0.032) and LDL cholesterol (P = 0.089). IL-6 plasma levels were higher in HIV positive subjects than in HIV negative individuals but lower than those in HIV negative subjects with CVD (mean ± SD 60.94 ± 17.55 versus 46.78 ± 9.9 versus 72.85 ± 35.4 pmol/L; median: 58.4 versus 47 versus 61.7 pg/mL) (P = 0.034) (Figure 4). We observed a statistical correlation between IL-6 plasma levels and the grade of stenosis in HIV positive patients (63.8 ± 17.7 versus 53.9 ± 13.5 pg/mL) (P = 0.045). Moreover, in HIV negative men with CVD the IL-6 mean value was higher in men with grade II/III stenosis than in those with grade I stenosis (71.9 versus 55.1 pg/mL) (P = 0.244). We found a positive correlation between IL-6 plasma levels and cholesterol LDL (P = 0.039). We did not find any significant correlation between OPG...
plasma levels, IL-6 plasma levels, and immune-virological parameters.

4. Discussion

HIV infected adults have higher risk of cardiovascular disease than the general population due to an accelerated atherosclerosis process [23]. Several risk factors play an important role in the pathogenesis and progression of atherosclerosis in HIV patients: both HAART toxicity (mitochondrial dysfunction and oxidative stress induced by thymidine analogues or even the accumulation of abnormal laminin A associated with HIV protease inhibitor) and the virus itself induce metabolic disorders, immune activation, and chronic inflammation [24, 25].

In this study, we enrolled 35 HIV infected men on suppressed HAART by at least 48 weeks with Framingham score <10%, 21 HIV negative individuals matched for age, gender, and Framingham score and 20 subjects with Framingham score >10%. We observed an increased prevalence of coronary stenosis in HIV infected patients than in uninfected controls as suggested by the absence of any abnormalities either in echocardiography or ECG in the latter group.

Heart CT scan is an accurate instrument for noninvasive assessment of coronary arteries which can substantially contribute to the diagnosis and management of cardiovascular disease [17]. In fact, it is able to distinguish calcified, partially calcified, and noncalcified plaques to quantify stenosis, their degree, and their extension. Although heart CT is not currently recommended in asymptomatic individuals, it could be considered in patients with low cardiovascular risk because of its ability to early identify small and soft plaques.

It is known that chemokines/cytokines including IL-6 and the OPG/RANK/RANKL system are involved in endothelial dysfunction leading to atherosclerosis development and progression. IL-6 and OPG plasma levels in HIV positive subjects were higher than those in healthy controls.

IL-6 is a proinflammatory and multifunctional cytokine which is secreted by many cell types such as macrophages, T lymphocytes and endothelial cells. Several reports have consistently shown that baseline levels of IL-6 are powerful predictor of cardiovascular events [3, 4, 26]. Our data confirm a correlation between increasing IL-6 plasma levels and severity of coronary stenosis, thus suggesting the proatherogenic role of this cytokine despite HIV-RNA suppression under HAART.

As already known, there is a link between residual HIV replication, inflammation, endothelial dysfunction, and atherosclerosis; residual viral replication, persistent viral expression, and the loss of immunoregulatory cells can induce immune activation and inflammation whose persistence
may result in endothelial dysfunction, vascular damage, and atherosclerosis [2].

Furthermore, OPG/RANK/RANKL system, member of TNF superfamily mostly implicated in bone remodelling, is involved in immune and in vascular system. In fact, RANKL, expressed by osteoblast cells and their precursors, activates its receptor, RANK, expressed by osteoclast cells and their precursors, promoting osteoclasts formation, activation, and prolonging osteoclasts survival. The effects of RANKL are blocked by the secretory glycoprotein osteoprotegerin which acts as a decoy receptor for RANKL. Changes in RANKL/OPG ratio are critical in the pathogenesis of bone disease [10].

The relationship between bone and vascular disease is shown; in this contest OPG could be considered as a bridge from bone to vascular system [12, 13]. The role of OPG in cardiovascular disease is still debated. In support of the antiatherosclerotic effect of OPG, recent findings showed an accelerated atherosclerotic lesion progression in OPG deficient mice [27]. Acting as a decoy receptor of RANKL, OPG blocks the RANKL effect by triggering endothelial chemotactic and angiogenic properties, by enhancing monocyte and T cell infiltration and osteogenic differentiation of multipotential vascular mesenchymal cells. On the other hand, OPG might contribute to endothelial dysfunction by blocking the RANKL signalling which is able to activate protective intracellular endothelial pathways such as the nitric oxide synthase pathway and increase the adhesion and migration of inflammatory cells through the endothelium and the activity of metalloproteases [15, 28, 29].

In our study, we found higher OPG plasma levels in HIV positive subjects than in healthy control but lower than those in HIV negative subjects with Framingham score >10% suggesting association between OPG plasma levels and cardiovascular disease. The increased OPG plasma concentration found in HIV positive patients with low cardiovascular risk may suggest that OPG is implicated in the early phase of atherosclerosis development process. Surprisingly, in HIV positive subjects we found that patients with grade I stenosis had higher OPG values rather than patients with grade II stenosis. Instead, in HIV negative patients with severe stenosis OPG plasma levels were higher than in HIV positive men. These apparently conflicting findings could be explained by the different composition and stage of the plaques; in fact, in HIV negative subjects with Framingham score >10% the calcium concentration in the plaque was higher than in HIV positive patients in whom most of the plaques were soft. OPG is expressed in different cell types including endothelial cells and vascular smooth muscle cells which are represented more in soft plaques. In this setting, OPG may indirectly prevent calcification by protecting arterial smooth muscle cells from apoptosis and OPG inactivation may lead to increased calcification which is present in older plaques [26].

Whereas in the bone system, OPG is considered as a counter-regulatory mechanism to protect bone loss; in the vascular system increased, OPG plasma levels may indicate endothelial damage [30–32]. However, further studies investigating the exact role of OPG in atherosclerosis are needed.

5. Conclusion

We showed that OPG plasma concentrations are associated with atherosclerosis in HIV infected subjects with a low Framingham score. OPG plasma measurement could be a useful and noninvasive tool in clinical practice in order to early discriminate subjects at risk of developing atherosclerosis.

Disclosure

The project described was supported by the Department of Public Health and Infectious Disease of “Sapienza” University of Rome.

Conflict of Interests

None of the authors have any conflicts or potential conflicts of interest.

References

[1] A. Hakeem, S. Bhatti, and M. Cilingiroglu, “The spectrum of atherosclerotic coronary artery disease in HIV patients,” Current Atherosclerosis Reports, vol. 12, no. 2, pp. 119–124, 2010.
[2] B. Coll, S. Parra, C. Alonso-Villaverde et al., “The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection,” Stroke, vol. 38, no. 9, pp. 2477–2484, 2007.
[3] S. W. Worm and P. Hsue, “Role of biomarkers in predicting CVD risk in the setting of HIV infection?” Current Opinion in HIV and AIDS, vol. 5, no. 6, pp. 467–472, 2010.
[4] O. Melander, C. Newton-Cheh, P. Almgren et al., “Novel and conventional biomarkers for prediction of incident cardiovascular events in the community,” Journal of the American Medical Association, vol. 302, no. 1, pp. 49–57, 2009.
[5] G. Biasillo, M. Leo, R. della Bona, and L. M. Biasucci, “Inflammatory biomarkers and coronary heart disease: from bench to bedside and back,” Internal and Emergency Medicine, vol. 5, no. 3, pp. 225–233, 2010.
[6] M. Guzmán-Fulgenicio, J. Medrano, N. Rallón et al., “Soluble markers of inflammation are associated with framingham scores in HIV-infected patients on suppressive antiretroviral therapy,” Journal of Infection, vol. 63, no. 5, pp. 382–390, 2011.
[7] A. C. Ross, N. Rizk, M. A. O’Riordan et al., “Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy,” Clinical Infectious Diseases, vol. 49, no. 7, pp. 1119–1127, 2009.
[8] X. Cheng, M. Kinosaki, R. Murali, and M. I. Greene, “The TNF receptor superfamily: role in immune inflammation and bone formation,” Immunologic Research, vol. 27, no. 2-3, pp. 287–294, 2003.
[9] D. Stejskal, J. Bartek, R. Pastorková, V. Růžička, I. Oral, and D. Horalík, “Osteoprotegerin, RANK, RANKL,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 145, no. 2, pp. 61–64, 2001.
[10] H. L. Wright, H. S. McCarthy, I. Middleton, and M. J. Marshall, “RANK, RANKL and osteoprotegerin in bone biology and disease,” Current Reviews in Musculoskeletal Medicine, vol. 2, no. 1, pp. 56–64, 2009.
[11] B. F. Boyce and L. Xing, “Functions of RANKL/RANK/OPG in bone modeling and remodeling,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 139–146, 2008.

[12] L. C. Hofbauer and M. Schoppet, “Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases,” Journal of the American Medical Association, vol. 292, no. 4, pp. 490–495, 2004.

[13] S. Kiechl, P. Werner, M. Knollfach, M. Furtner, J. Willeit, and G. Schett, “The osteoprotegerin/RANKL/RANKL system: a bone key to vascular disease,” Expert Review of Cardiovascular Therapy, vol. 4, no. 6, pp. 801–811, 2006.

[14] P. Collin-Osdoby, “Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin,” Circulation Research, vol. 95, no. 11, pp. 1046–1057, 2004.

[15] A. van Campenhout and J. Golledge, “Osteoprotegerin, vascular calcification and atherosclerosis,” Atherosclerosis, vol. 204, no. 2, pp. 321–329, 2009.

[16] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004.

[17] C. R. Hamilton-Craig, D. Friedman, and S. Achenbach, “Cardiac computed tomography-evidence, limitations and clinical application,” Heart Lung and Circulation, vol. 21, no. 2, pp. 70–81, 2012.

[18] G. D’Etto, M. Francone, M. Mancone et al., “Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects,” Journal of Infection, vol. 64, no. 1, pp. 82–88, 2012.

[19] M. D. Cerqueira, N. J. Weissman, V. Dilsizian et al., “Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association,” The international journal of cardiovascular imaging, vol. 18, no. 1, pp. 539–542, 2002.

[20] W. G. Austen, J. E. Edwards, R. L. Frye et al., “A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association,” Circulation, vol. 5, pp. 15–40, 1975.

[21] S. B. King 3rd, S. C. Smith Jr., D. A. Morrison et al., “Focused update of the ACC/AHA/SCAI, 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 Writing group to review new evidence and update the ACC/AHA/SCAI, 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee,” Circulation, vol. 117, pp. 261–295, 2008.

[22] M. R. Patel, G. J. Dehmer, J. W. Hirshfeld, P. K. Smith, and J. A. Speratus, “ACC/CSC/STS/AATS/HAASNC Appropriateness criteria for coronary revascularization. A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear,” Journal of the American College of Cardiology, vol. 53, no. 6, pp. 530–553, 2009.

[23] J. Lo, S. Abbara, L. Shutman et al., “Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men,” AIDS, vol. 24, no. 2, pp. 243–253, 2010.

[24] M. W. Lorenz, C. Stephan, A. Harmjanz et al., “Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis,” Atherosclerosis, vol. 196, no. 2, pp. 720–726, 2008.

[25] S. G. Deeks, “Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy,” Topics in HIV Medicine, vol. 17, no. 4, pp. 118–123, 2009.

[26] W. Lieb, P. Gona, M. G. Larson et al., “Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1849–1854, 2010.

[27] B. J. Bennett, M. Scatena, E. A. Kirk et al., “Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 9, pp. 2117–2124, 2006.

[28] F. Montecucco, S. Steffens, and F. Mach, “The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?” Clinical & Developmental Immunology, vol. 2007, Article ID 75805, 8 pages, 2007.

[29] A. Quercioli, G. Luciano Viviani, F. Dallegri, F. Mach, and F. Montecucco, “Receptor activator of nuclear factor kappaB ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification,” Critical Pathways in Cardiology, vol. 9, no. 4, pp. 227–230, 2010.

[30] A. Vik, E. B. Mathiesen, J. Brox et al., “Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: The Tromsø Study,” Journal of Thrombosis and Haemostasis, vol. 9, no. 4, pp. 638–644, 2011.

[31] M. Schoppet, A. M. Sattler, J. R. Schaefer, M. Herzum, B. Maisch, and L. Hofbauer, “Increased osteoprotegerin serum levels in men with coronary artery disease,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1024–1028, 2003.

[32] J. J. Hwang, J. Wei, S. Abbara, S. K. Grinspoon, and J. Lo, “Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 3, pp. 359–363, 2012.
